News Briefing channel feed

Rick Klaus­ner's Lyell part­ners, helps fund Eu­reka's work on cell ther­a­pies; Blue­print bounces high­er on PhII

6 years ago

Cure­Vac founder back at the helm; Mer­ck ex­tends im­munomod­u­la­to­ry drug dis­cov­ery pro­gram with Sutro

6 years ago

Bris­tol My­ers scores new FDA nod for Op­di­vo/Yer­voy com­bo; US Army wants Gilead­'s po­ten­tial Covid-19 drug for in­fect­ed troops

6 years ago

Sy­neos up for sale — re­port; Takeda's Nin­laro fails PhI­II in mul­ti­ple myelo­ma; EMA braces for drug short­age

6 years ago

In­ovio files for $50M of­fer­ing amid Covid-19 vac­cine hunt; Zy­dus Cadi­la signs on with XO­MA on IL-2 deal

6 years ago

Coro­n­avirus up­date: Trump signs $8.3B spend­ing bill in­to law; Pfiz­er con­sid­ers mR­NA vac­cine pact with BioN­Tech

6 years ago

No­body but Deer­field wants Melin­ta; No­var­tis finds a new drug dis­cov­ery part­ner

6 years ago

Bris­tol-My­ers joins forces with dig­i­tal ther­a­peu­tics co; Wear­able car­diovert­er de­fib­ril­la­tor scores $145M+ in Se­ries C haul

6 years ago

$7.5B in emer­gency con­gres­sion­al coro­n­avirus prep; Sick­le cell biotech sets terms for IPO

6 years ago

No­var­tis re­it­er­ates its faith in Eylea ri­val Beovu; An­ti-NGF drug from Lil­ly, Pfiz­er is ac­cept­ed for FDA re­view

6 years ago

Sage con­firms sus­pen­sion of 2 de­pres­sion tri­als af­ter PhI­II flop; Es­pe­ri­on fol­lows up maid­en ap­proval with com­bo OK

6 years ago

Tes­sa gets RMAT des­ig­na­tion for new CAR-T; FDA ad­comm nar­row­ly votes to ex­pand Eli Lil­ly NSCLC la­bel

6 years ago

Scott Got­tlieb in the run­ning for pos­si­ble coro­n­avirus czar; The drug Van­da sued the FDA over fails a piv­otal study

6 years ago

IDO-de­rived can­cer vac­cine scores in com­bo tri­al with Keytru­da; Vir teams up with WuXi on coro­n­avirus an­ti­bod­ies

6 years ago

Eli Lil­ly scores ex­pand­ed MACE la­bel for Trulic­i­ty; Gilead­'s CAR-T Yescar­ta gets in Chi­na re­view line

6 years ago

Gen­fit de­lays high-stakes PhI­II NASH read­out; Bris­tol-My­ers grabs first Op­di­vo OK in esophageal can­cer

6 years ago

Heron's Ground­hog Day; Vi­for forms JV with Fre­se­nius Kabi in Chi­na

6 years ago

In­cyte's top­i­cal Jakafi scores again in eczema Phase III; Pri­or­i­ty re­view lines Roche's Tecen­triq up for new lung can­cer nod

6 years ago

Two fast track des­ig­na­tions for Corey Good­man's new start­up; Vi­for/Ake­bia se­cure pri­or­i­ty re­view vouch­er

6 years ago

As­traZeneca sweeps two can­cer drugs to the scrap heap; Epizyme nabs pri­or­i­ty re­view for sec­ond rare can­cer NDA

6 years ago

Elan­co grabs $140M in deal with French phar­ma com­pa­ny; An­oth­er com­pa­ny an­nounces a coro­n­avirus vac­cine hunt

6 years ago
Coronavirus

Pre­vail's gene ther­a­py scores or­phan, rare pe­di­atric dis­ease priv­i­leges; Ger­many's ITM se­cures €40M loan

6 years ago

The Wuhan coro­n­avirus has an of­fi­cial name: COVID-19; Rev­o­lu­tion Med­i­cines up­sizes IPO terms

6 years ago
Coronavirus

Eye drop de­vel­op­er Oculis show­cas­es pos­i­tive PhII da­ta; Aque­s­tive hunts for an­oth­er FDA OK

6 years ago
First page Previous page 42434445464748 Next page Last page
A service from the Financial Times